Cheng Du Sheng Nuo Biotec Co., Ltd. Class A

As of June 30, 2026, Cheng Du Sheng Nuo Biotec Co., Ltd. Class A carries a market capitalization of 5.96B, placing it among publicly traded companies globally. Its enterprise value stands at 6.24B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Cheng Du Sheng Nuo Biotec Co., Ltd. Class A's next confirmed earnings release is scheduled for October 28, 2026.

As of June 30, 2026, Cheng Du Sheng Nuo Biotec Co., Ltd. Class A has 220.34M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Cheng Du Sheng Nuo Biotec Co., Ltd. Class A maintains a current ratio of 1.97, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Cheng Du Sheng Nuo Biotec Co., Ltd. Class A recorded 34.72M in income tax expense.

As of the close on October 22, 2026, Cheng Du Sheng Nuo Biotec Co., Ltd. Class A's stock has declined approximately 45.65% over the past 52 weeks. The 50-day moving average sits at 22.11, while the 200-day moving average is 25.36.

As of June 30, 2026, Cheng Du Sheng Nuo Biotec Co., Ltd. Class A holds 352.71M in cash and equivalents against 638.74M in total debt, resulting in a net debt position of 309.22M. Total book value stands at 1.14B, with working capital of 497.25M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Cheng Du Sheng Nuo Biotec Co., Ltd. Class A paid dividends of 0.32 per share.

Cheng Du Sheng Nuo Biotec Co., Ltd. Class A's most recent stock split took place on June 5, 2026 with a 5:7 split ratio.